Researchers have identified an enzyme linked to pregnancy-induced hypertension – also known as pre-eclampsia – a pregnancy complication characterized by high blood pressure and swelling due to fluid retention. The findings could be used to better screen for – and treat – this condition.
Pregnancy-induced hypertension, which occurs in approximately 10 percent of pregnancies, is a major cause of maternal and fetal deaths, yet the cause is unknown.
The study, led by researchers in Cleveland Clinic's Lerner Research Institute, examined mice for corin – an enzyme normally present in the heart – and determined that the deficiency of this enzyme in the uterus may be an underlying cause of the disease. The study was published today in Nature.
Pregnancy poses a major challenge for controlling blood pressure. As blood volume increases, maintaining normal blood pressure becomes more difficult. During pregnancy, the narrow, curly uterine arteries are enlarged to thin-walled vessels, an adaptive change important for maintaining normal maternal blood pressure and boosting blood flow to the fetus. However, in pregnant women with hypertension, the changes in uterine arteries become defective.
While this study was initially conducted on mice, the researchers extended their study to patients with pre-eclampsia. The researchers found that many pre-eclamptic patients had low levels of corin in their uterus, and corin gene mutations in pre-eclamptic patients were identified.
"Additional studies on corin or its related molecules may help to develop new methods to diagnose and treat pregnancy-induced hypertension," said Qingyu Wu, M.D., Ph.D., a researcher in the Department of Molecular Cardiology in Cleveland Clinic's Lerner Research Institute and the lead researcher on the study.
In this study, Dr. Wu and his staff collaborated with investigators at the Cyrus Tang Hematology Center of Soochow University in Suzhou, China, and Shanghai Jiaotong University in China, who conducted clinical studies.
About Cleveland ClinicCleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. About 2,800 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. Cleveland Clinic Health System includes a main campus near downtown Cleveland, eight community hospitals and 18 Family Health Centers in Northeast Ohio, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and opening in 2013, Cleveland Clinic Abu Dhabi. In 2010, there were 4 million visits throughout the Cleveland Clinic health system and 167,000 hospital admissions. Patients came for treatment from every state and from more than 100 countries. Visit us at www.clevelandclinic.org. Follow us at www.twitter.com/ClevelandClinic.
Dan Doron | EurekAlert!
Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center
Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
17.01.2018 | Ecology, The Environment and Conservation
17.01.2018 | Physics and Astronomy
17.01.2018 | Awards Funding